Ironwood Pharmaceuticals | IRWD - Gross Profit On Sales


Ironwood Pharmaceuticals reported $85.24M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Almirall EUR 429.87M 180.02M Dec/2025
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
Ardelyx USD 89.66M 24.7M Mar/2026
Astellas Pharma JPY 482.54B 38.28B Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
Charles River Laboratories USD 348.78M 69.47M Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 11.24M 19.87M Mar/2026
Moderna USD -566M 792M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 133.91M 7.27M Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024